AZD7325 + AZD7325 + AZD7325 + Placebo

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Anxiety Disorders

Conditions

Anxiety Disorders

Trial Timeline

Dec 1, 2008 → May 1, 2009

NCT ID

NCT00808249

About AZD7325 + AZD7325 + AZD7325 + Placebo

AZD7325 + AZD7325 + AZD7325 + Placebo is a phase 2 stage product being developed by AstraZeneca for Anxiety Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT00808249. Target conditions include Anxiety Disorders.

What happened to similar drugs?

19 of 20 similar drugs in Anxiety Disorders were approved

Approved (19) Terminated (2) Active (1)

✅Duloxetine + PlaceboEli LillyApproved

✅Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatmentSumitomo PharmaApproved

✅Cariprazine + PlaceboAbbVieApproved

✅EscitalopramAbbVieApproved

✅QuetiapineAstraZenecaApproved

✅Quetiapine extended release tablet + PlaceboAstraZenecaApproved

✅QuetiapineAstraZenecaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00808249	Phase 2	Completed	Dec 1, 2008	May 1, 2009	Anxiety Disorders

Competing Products

20 competing products in Anxiety Disorders

See all competitors

Product	Company	Stage	Hype Score
Duloxetine + venlafaxine + placebo	Eli Lilly	Phase 3	40
ONO-1110 + Placebo	Ono Pharmaceutical	Phase 2	39
Duloxetine + Placebo	Eli Lilly	Phase 3	40
duloxetine hydrochloride + placebo	Eli Lilly	Phase 3	40
Duloxetine + Placebo	Eli Lilly	Approved	43
Duloxetine Hydrochloride + placebo	Eli Lilly	Phase 3	40
duloxetine + placebo	Eli Lilly	Phase 3	40
Duloxetine + venlafaxine + placebo	Eli Lilly	Phase 3	40
Duloxetine + Placebo	Eli Lilly	Phase 3	40
eszopiclone + eszopiclone + Placebo	Sumitomo Pharma	Phase 2	35
Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatment	Sumitomo Pharma	Approved	43
risperidone oral tablets	Johnson & Johnson	Phase 3	40
ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT)	AbbVie	Phase 2	42
Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/day	AbbVie	Phase 2	27
ABBV-932 + Placebo	AbbVie	Phase 1	29
Cariprazine + Placebo	AbbVie	Approved	43
Escitalopram	AbbVie	Approved	43
Quetiapine	AstraZeneca	Approved	43
Quetiapine extended release tablet + Placebo	AstraZeneca	Approved	43
AZD7325 + Radioligand (11C) flumazenil	AstraZeneca	Phase 1	29